Long non-coding RNA NNT-AS1 sponges miR-424/E2F1 to promote the tumorigenesis and cell cycle progression of gastric cancer

Beibei Chen¹ | Qingfang Zhao¹ | Lulu Guan¹ | Huifang Lv¹ | Liangyu Bie¹ | Jinx Huang² | Xiao-Bing Chen¹

¹Department of Gastrointestinal Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Cancer Hospital of Henan Province, Henan, China
²Department of Gastrointestinal Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Cancer Hospital of Henan Province, Henan, China

Correspondence
Xiao-Bing Chen
Email: chenxiaobing_medic@yeah.net

Funding Information
Project of National Natural Science Foundation of China, Grant/Award Number: 81472714; Project of international scientific and technological cooperation research of Henan Province, Grant/Award Number: 182102410023

Abstract
Long non-coding RNAs (lncRNAs) have been illustrated to function as important regulators in carcinogenesis and cancer progression. However, the roles of lncRNA NNT-AS1 in gastric cancer remain unclear. In the present study, we investigate the biological role of NNT-AS1 in gastric cancer tumorigenesis. Results revealed that NNT-AS1 expression level was significantly up-regulated in GC tissue and cell lines compared with adjacent normal tissue and normal cell lines. The ectopic overexpression of NNT-AS1 indicated the poor prognosis of GC patients. In vitro experiments validated that NNT-AS1 knockdown suppressed the proliferation and invasion ability and induced the GC cell cycle progression arrest at G0/G1 phase. In vivo xenograft assay, NNT-AS1 silencing decreased the tumour growth of GC cells. Bioinformatics online program predicted that miR-424 targeted the 3'-UTR of NNT-AS1. Luciferase reporter assay, RNA-immunoprecipitation (RIP) and RNA pull-down assay validated the molecular binding within NNT-AS1 and miR-424, therefore jointly forming the RNA-induced silencing complex (RISC). Moreover, E2F1 was verified to act as the target gene of NNT-AS1/miR-424, indicating the NNT-AS1/miR-424/E2F1 axis. In conclusion, our study indicates that NNT-AS1 sponges miR-424/E2F1 to facilitate GC tumorigenesis and cycle progress, revealing the oncogenic role of NNT-AS1 for GC.

KEYWORDS
cell cycle progression, E2F1, gastric cancer, miR-424, NNT-AS1

1 | INTRODUCTION

Gastric cancer (GC) is one of the most common gastrointestinal cancers and ranks as the fifth most common cancers.¹-³ Along with the progress of more comprehensive therapy techniques, the mortality rate of GC patients is decreasing in recent years; however, there are still huge quantity GC patients who are diagnosed at an advanced stage with lymphatic or distant metastasis in the absence of specific symptoms.⁴,⁵ Because of the high rates of postsurgical recurrence and metastasis, the prognosis of GC patients diagnosed as advanced-stage is pessimistically bad.⁶ Therefore, more attention should be devoted to the pathologic mechanism research.

Long non-coding RNAs (lncRNAs) are a type of non-coding RNAs (ncRNAs) with more than 200 nucleotides.⁷,⁸ Non-coding
RNAs (ncRNAs) account for a large proportion of transcriptome, which are divided into short non-coding RNAs and IncRNAs according to their length. Increasing evidence has indicated the extensive biological role of IncRNAs on multiple tumour pathological process, for example proliferation, invasion, metastasis and recrudescence. For the tumorigenesis of GC, more and more IncRNAs have been identified to modulate the pathological process. For instance, long intergenic non-coding RNA 01296 (LINC01296) acts as oncogenic IncRNA in GC carcinogenesis and aggravates gastric cancer cells progression via LINC01296/miR-122/MMP-9 regulatory pathway.

In the pre-experiments of our study, we focus on several candidate IncRNAs, and then we measured the expression levels of these candidate IncRNAs in cancer tissue using RT-PCR. After comparing, we found that the IncRNA NNT-AS1 expression level is up-regulated in GC tissue samples and cells. NNT-AS1 has been found to act as oncogene in human cancer. Besides, the roles and molecular mechanism of IncRNA NNT-AS1 on GC tumorigenesis are unknown and never reported. Thus, we choose IncRNA NNT-AS1 as our research object. In the present study, we aim to investigate the expression of IncRNA NNT-AS1 in GC cells tumorigenesis. Besides, we analysed the relationship between NNT-AS1 levels and the clinicopathological features of GC and investigated the biological effect and mechanisms of NNT-AS1 on the phenotypes of GC cells in vitro and in vivo. Results indicate that NNT-AS1 is a vital regulator in the cell cycle progression of GC through sponging miR-424/E2F1.

2 | MATERIALS AND METHODS

2.1 | Patient samples

A total of 48 GC samples were collected from August 2015 to July 2017 at The Affiliated Cancer Hospital of Zhengzhou University. There are no any patients who had received preoperative chemotherapy before this study. The tissues were excised during the surgery and snap-frozen in liquid nitrogen. This study was approved by the Ethic Committee of The Affiliated Cancer Hospital of Zhengzhou University. All written informed consents had been collected from every patient before surgery.

2.2 | Cell culture and transfection

The human GC cell lines (SGC-7901, BGC-823, MGC-803 and MKN-45) were obtained from the Chinese Institute of Biochemistry and Cell Biology (Shanghai, China). Normal gastric mucosa cell lineGES-1 was purchased from American Type Culture Collection (ATCC, Rockville, MD, USA). Cell lines were cultured in Dulbecco’s Modified Eagle’s medium (DMEM, Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine serum (FBS, Gibco, USA) at 37°C in a humidified incubator containing 5% CO2. For transfection, miR-424 mimics, miR-424 inhibitor and siRNAs targeting NNT-AS1 were provided by GenePharma (Shanghai, China) for silencing or up-regulation. Transfection was performed using Lipofectamine2000 (Invitrogen, USA) following the instructions of manufacturer. All assays were repeated at least 3 times.

2.3 | Quantitative reverse transcription polymerase chain reaction (RT-PCR)

Total RNAs were extracted from the tumour tissue and adjacent normal tissues or cells using TRIzol reagent (Life Technologies, Carlsbad, CA, USA) following the manufacturer’s protocol. PrimeScript RT Reagent Kit (TaKaRa, Dalian, China) was used to synthesize complementary DNA (cDNA). The qRT-PCR was performed using SYBR Premix Ex Taq (TaKaRa). The primers for PCR were as follows: NNT-AS1, forward 5’-AGTTCACCAAGTTTCTTCA-3’, reverse 5’-AGGT TT GGCCAGCATAGAC-3’; miR-424, forward, 5’-GCTCGAGATATGGAG GGGCGCC-3’, reverse, 5’-GGAACGGCCAGACACGT A-TCC-3’. Each expression level was calculated with the 2^(-ΔΔCt) method and β-actin acted as the endogenous control to normalize the data. The PCR was performed in triplicate.

2.4 | Cell Counting Kit-8 assay

Cell proliferation assay was performed with Cell Counting Kit-8 (CCK-8; Dojindo Laboratories, Kumamoto, Japan). GC cells (MGC-803, SGC-7901) were seeded into 96-well plates at a density of 1 x 10^3 per well. About 10 µL of CCK-8 solution was added into each well at indicated time points. After incubation at 37°C for 2 hours, the absorbance was measured using an automatic microplate at 450 nm.

2.5 | Transwell invasion assay

GC cells (MGC-803, SGC-7901) were transfected with indicated oligonucleotides. Then, 24-well transwell chamber (Costar, MA, USA) with or without matrigel coating was performed for invasion. Briefly, GC cells (1 x 10^5 cells per well) were suspended in serum-free medium and transferred to the upper compartment which was added with 10% FBS while the lower compartment was filled with 600-µL DMEM supplemented with 10% FBS. After incubation for 24 hours at 37°C, cells were fixed with ice-cold methanol for 30 minutes and stained with 0.1% crystal violet for 10 minutes. The invaded cell number was determined in 5 randomly selected high-power fields. Assay was performed in triplicate.

2.6 | Western blot analysis

The expression of E2F1 protein in GC cells was detected by performing immunoblotting. Cells were lysed in RIPA buffer (pH 7.4) with protease and phosphatase inhibitors (Roche, Complete Mini). Equal amount of protein was loaded onto a SDS-PAGE gel and transferred to PVDF membrane. The membrane was probed with the first antibody; E2F1 (1:1000, Abcam, MA, USA), CDK6 (1:1000, Abcam), Cyclin E (1:1000, Abcam), Cyclin D1 (1:1000, Abcam) and
GAPDH (1:1000, Abcam) at 4°C overnight. Then, blots were incubated with HRP-conjugated secondary antibody (1:5000). The antibodies were detected using enhanced chemiluminescence reagent (32109; Thermo Fisher Scientific).

2.7 | Luciferase reporter assay

For Luciferase assays, NNT-AS1 wild type with potential miR-424 binding sites or mutant sites was generated by Sangon Biotech (Shanghai, China), and then fused with the luciferase reporter vector psi-CHECK-2 (Promega, Madison, WI, USA). SGC-7901 cells (2 × 10⁶ cells/well) were seeded into 96-well plates. Cells were co-transfected with luciferase plasmids and miRNA mimics or controls. Cells were cultured in 12-well plates and transfected with 5 ng plasmid and 5 ng Renilla using Dual-Luciferase Reporter Assay System (Promega). Every analysis was performed 3 times.

2.8 | RNA immunoprecipitation (RIP)

RNA immunoprecipitation (RIP) assays were performed as previously described. Wild-type NNT-AS1 or mutant NNT-AS1 were synthesized and then cloned into SGC-7901 cells. SGC-7901 cells were also co-transfected with miR-NC or miR-424 mimic. Cells were lysed by lysis buffer containing a protease inhibitor cocktail and RNase inhibitor. Magnetic beads were pre-incubated with an anti-GFP antibody (Abcam) or anti-rabbit IgG (Millipore) for 1 hour at room temperature, and lysates were immunoprecipitated with beads at 4°C overnight. After 48 hours, cells were used to perform RIP assay using an anti-AGO2 antibody (Millipore) as described above.

2.9 | RNA pull-down assay

RNA pull-down assay was performed using Magnetic RNA-Protein Pull-Down Kit (Pierce, USA) according to the manufacturer’s instructions. Briefly, miRNA was labelled using biotin and then transfected into SGC-7901 cells. A biotinylated miRNA without complementary sites with NNT-AS1 acted as negative control. After 48 hours, cells were harvested for biotin-based pull-down assay. The expression or enrichment was measured using RT-PCR.

2.10 | Xenograft in vivo mice assay

Ten athymic BALB/C nude mice (4-week old, 8-10 g) were all purchased from Shanghai Experimental Animal Center of Chinese Academy of Sciences (Shanghai, China). SGC-7901 cells (3 × 10⁶) transfected with lentivirus-mediated NNT-AS1 shRNA (sh-NNT-AS1) or negative control (sh-NC) were subcutaneously injected into nude mice. Tumour volumes were measured every 3 days and calculated according to 0.5 × length × width². The in vivo assay was performed following the approval by the Animal Care and Experiment Committee of The Affiliated Cancer Hospital of Zhengzhou University.

2.11 | Statistical analysis

Statistical analyses and data calculation were performed using the SPSS19.0 (IBM, SPSS, Chicago, IL, USA) software and graphed using GraphPad Prism 6 (GraphPad Software, San Diego, CA, USA). Overall survival curves were calculated using Kaplan-Meier analysis and the log-rank test. Pearson correlation coefficient was used to analyse the correlations. Comparisons between groups were analysed by the t tests χ² test, one-way analysis of variance (ANOVA). The differences were considered statistically significant at P < .05.

3 | RESULTS

3.1 | LncRNA NNT-AS1 was highly expressed in GC tissues and cells, and indicated poor prognosis of GC patients

To verify the expression of NNT-AS1 in GC tumour tissue and cells, RT-PCR was performed on these collected samples and cultured cells. The clinicopathologic data of GC patients were presented in Table 1. Results revealed that NNT-AS1 expression was significantly up-regulated in these collected GC tissue samples.

| Table 1 Relationship between NNT-AS1 expression and clinicopathological characteristics of GC patients |
|---------------------------------------------------------------|
|                       | NNT-AS1                  |
| Case (48)             | Low (N = 21) | High (N = 27) | P value |
| Age                   |              |
| <60                   | 26           | 11            | 15      | .705   |
| ≥60                   | 22           | 10            | 12      |
| Gender                |              |
| Male                  | 28           | 12            | 16      | .694   |
| Female                | 20           | 9             | 11      |
| Histological grade    |              |
| Well/moderate         | 16           | 7             | 9       | .114   |
| Poor/other            | 32           | 14            | 18      |
| T stage               |              |
| T1-T2                 | 29           | 14            | 15      | .022*  |
| T3-T4                 | 19           | 7             | 12      |
| Lymphatic metastasis  |              |
| Present               | 35           | 18            | 17      | .002*  |
| Absent                | 13           | 3             | 10      |
| TNM stage             |              |
| I-II                  | 18           | 8             | 10      | .003*  |
| III-IV                | 30           | 13            | 17      |

TNM, tumor-node-metastasis; Well, Well-differentiated adenocarcinoma; Moderate, moderately differentiated adenocarcinoma; Poor, poorly differentiated adenocarcinoma; Other, other histological type.

*P < .05 represents statistical differences.
compared with adjacent normal tissue (Figure 1A). Meanwhile, RT-PCR revealed that NNT-AS1 expression was also significantly up-regulated in GC cell lines (BGC-823, MGC-803, AGS, SGC-7901, MKN-45) compared with normal gastric mucosa cell line (GES-1) (Figure 1B). According to median value of NNT-AS1 expression, the whole group was divided into high NNT-AS1 expression group (n = 21) and low NNT-AS1 expression group (n = 27) (Figure 1C). Overall survival rate of GC patients was calculated using Kaplan-Meier curves and log-rank test, showing that GC patients with high NNT-AS1 levels had poor prognosis than those with low NNT-AS1 level (Figure 1D). In summary, the data concluded that lncRNA NNT-AS1 was highly expressed in GC tissues and cells, and the ectopic overexpression indicated poor prognosis of GC patients.

3.2 | NNT-AS1 knockdown induced the GC cell cycle progression arrest at G0/G1 phase

Although the ectopic overexpression of lncRNA NNT-AS1 had been identified in GC tissues and cells, the biologic role of it on GC tumorigenesis was still ambiguous. RT-PCR revealed that the cellular localization of NNT-AS1 was mainly in cytoplasm, instead of nuclear (Figure 2A). Small interfering RNAs (siRNAs) targeting NNT-AS1 were transfected into GC cell lines (SGC-7901, MGC803) to decrease the expression levels of NNT-AS1 (Figure 2B). Cell cycle distribution measured by flow cytometry analysis showed that NNT-AS1 knockdown increased the cell distribution at G0/G1 phase, suggesting the cycle progression arrest at G0/G1 phase (Figure 2C, D). Western blot analysis revealed that NNT-AS1 knockdown significantly decreased the cycle-related protein levels of CDK6, Cyclin E and Cyclin D1, compared with control transfection in GC cell lines (SGC-7901, MGC803) (Figure 2E, F). Overall, the above data concluded that NNT-AS1 was mainly located in the cytoplasm, and NNT-AS1 knockdown induced the GC cell cycle progression arrest at G0/G1 phase.

3.3 | NNT-AS1 knockdown suppressed the proliferation and invasion ability in vitro, and inhibited the GC tumour growth in vivo

Subsequently, we tested the role of NNT-AS1 knockdown on GC tumour phenotype using in vitro and in vivo experiments. CCK-8 assay showed that NNT-AS1 knockdown suppressed the proliferation ability of GC cell (SGC-7901, MGC803) compared with control group (Figure 3A, B). Transwell invasion assay showed that NNT-AS1 knockdown inhibited the invasive cells compared with control groups (Figure 3C, D). Xenograft in vivo assay was performed to verify the function of NNT-AS1 on GC tumour growth (Figure 3E). Results showed that NNT-AS1 knockdown induced by lentivirus-mediated transfection significantly decreased the tumour volume of GC cells (Figure 3F), besides suppressing the tumour weight after killing (Figure 3G). In summary, the above results concluded that NNT-AS1 knockdown suppressed the proliferation and invasion ability of GC cells in vitro, and inhibited the GC tumour growth in vivo.

3.4 | NNT-AS1 targeted miR-424 as miRNA ‘sponge’

Prior assay revealed that the cellular localization of NNT-AS1 was mainly in the cytoplasm, instead of nuclear (Figure 2A). Therefore, we assumed that NNT-AS1 might function as miRNA ‘sponge’ in the GC tumorigenesis. Bioinformatics online program (StarBase, http://starbase.sysu.edu.cn) predicted that miR-424 shared with complementary binding sites with NNT-AS1 at 3'-Untranslated Regions (3'-UTR) (Figure 4A). Luciferase reporter assay showed...
that NNT-AS1 combined with miR-424 at 3'-UTR with molecular binding (Figure 4B). RIP assay indicated that both NNT-AS1 and miR-424 were significantly enriched in Ago2 immunoprecipitate compared to IgG-pellet, suggesting that both NNT-AS1 and miR-424 were in the same RNA-induced silencing complex (RISC) (Figure 4C). Besides, biotin-avidin pull-down assay was performed to determine whether miR-424 could directly bind with NNT-AS1. Results showed that miR-424 directly binds with NNT-AS1 (Figure 4D). RT-PCR showed that miR-424 was significantly over-expressed in GC cell (SGC-7901, MGC803) transfected with si-NNT-AS1 or si-NC (Figure 4E). Meanwhile, miR-424 expression was significantly down-regulated in GC cell lines (MGC-803, SGC-7901) when compared with normal gastric mucosa cell line (GES-1) (Figure 4F). Moreover, NNT-AS1 expression was also significantly down-regulated in GC cell lines (MGC-803, SGC-7901) transfected with miR-424 mimics or control (Figure 4G). Overall, the results concluded that NNT-AS1 targeted miR-424 with complementary binding sites, acting as a miRNA ‘sponge’.

### 3.5 NNT-AS1/miR-424 targeted E2F1 in the cycle progression regulation of GC cells

Moreover, bioinformatics programs (TargetScan, http://www.targetscan.org) predicted that miR-424 targeted the 3'-UTR of E2F1 with complementary binding sites (Figure 5A). Moreover, luciferase reporter assay confirmed the molecular interaction within miR-424 and E2F1 mRNA. In SGC-7901 cells, Western blot assay showed that E2F1 protein expression was significantly up-regulated when transfected with miR-424 inhibitor, while it was down-regulated when transfected with miR-424 mimics (Figure 5B). Furthermore, in
SGC-7901 cells, Western blot assay validated that E2F1 protein expression was decreased when transfected with si-NNT-AS1, which was reversed by the co-transfection of miR-424 inhibitor (Figure 5C). Pearson’s correlation analysis revealed that E2F1 expression was negatively correlated to miR-424 expression in 15 cases of GC patients samples (Figure 5D). Overall, these data concluded that NNT-AS1/miR-424 targeted E2F1 protein expression in the cycle progression regulation of GC cells in vitro.

4 | DISCUSSION

Long non-coding RNAs have recently emerged as an important regulator on transcriptional and post-transcriptional regulation of several diseases, including cancers.\textsuperscript{14-16} LncRNA NNT-AS1 has been found to participate in the tumorigenesis of hepatocellular carcinoma, cervical cancer and colorectal cancer.\textsuperscript{17-19} In the pre-experiments of our study, we found that the lncRNA NNT-AS1 expression level was up-regulated in GC tissue samples and cells. Besides, the roles and molecular mechanism of lncRNA NNT-AS1 on GC tumorigenesis are unknown and never reported. Thus, we choose lncRNA NNT-AS1 as our research object. In the present study, our study investigates the role of lncRNA NNT-AS1 in gastric cancer (GC) tumorigenesis and identifies the underlying mechanism.

During the carcinogenesis of GC, a great deal of lncRNAs might be abnormally expressed.\textsuperscript{20,21} Generally, the significantly dysregulated lncRNAs might involve the pathological process and exert vital roles by regulating multiple progression. In our study, we found that lncRNA NNT-AS1 was significantly high-expressed in gastric cancer
tissue and cell lines when compared with adjacent normal tissue and normal cells. Besides, the ectopic overexpression of NNT-AS1 indicates poor prognosis of GC patients calculated using Kaplan-Meier curves and log-rank test. Therefore, the evidence proved the oncogenic role of NNT-AS1 in GC tumorigenesis.

The oncogenesis of GC is a complex pathophysiological process involved in multifarious pathophysiological process, including proliferation, invasion, metastasis and cycle progression. In subsequent functional experiments in vitro, results revealed that NNT-AS1 knockdown suppressed the proliferation and invasion ability in vitro, induced the GC cell cycle progression arrest at G0/G1 phase and inhibited the GC tumour growth in vivo.

Bioinformatics online tools predicted the complementary binding within NNT-AS1 and miR-424. Luciferase reporter assay confirmed the molecular binding at 3'-UTR. Moreover, RIP assay indicated that NNT-AS1 and miR-424 form the RNA-induced silencing complex (RISC). Therefore, we validate the direct molecular interaction within NNT-AS1 and miR-424, illustrates that NNT-AS1 functions as miR-424 'sponge'.

Long non-coding RNAs are a type of non-coding RNA (ncRNA) without protein-coding ability. Up to now, the most common regulatory mechanism for IncRNA is the miRNA 'sponge' theory. In our study, our data indicate that NNT-AS1 harbours miR-424 by 3'-UTR binding, while miR-424 also targets the 3'-UTR of E2F1.
mRNA. E2F1 protein is an important transcription factor among E2F family, which is a vital regulator in cell cycle regulation and apoptosis. Emerging evidences have proved that E2F1 closely controls the cellular process from G1 to S phase, acting as a critical element for cycle progression. In addition, previous results reveal that NNT-AS1 knockdown suppressed the cycle-related protein levels of CDK6, Cyclin E and Cyclin D1 in GC cell lines. Besides, NNT-AS1 knockdown induced G0/G1 phase arrest. Based on the above findings, we conclude that NNT-AS1 exerts the cycle inhibitive function through targeting miR-424/E2F1 axis. E2F1 is found to be aberrantly high-expressed in gastric cancer, and enhanced E2F1 expression promotes proliferation, while E2F1 low expression decreased cell proliferation by blocking cell cycle in GC cells.\(^26\) Moreover, R-424-5p is found to be up-regulated in GC tissues and cells, and its high-expression could promote the proliferation of GC cells.\(^27\)

More than NNT-AS1, other lncRNAs also modulate the cellular process of GC cells.\(^28\) For example, lncRNA SNHG6 is overexpressed in gastric cancer tissues and cell lines, and SNHG6 could epigenetically silence p27 and competitively sponge miR-101-3p to regulate ZEB1.\(^29\) In HCC tumorigenesis, NNT-AS1 knockdown inhibited the HCC cells progression via miR-363 thereby targeting CDK6 expression.\(^18\) Therefore, our study firstly confirmed the oncogenic role of lncRNA NNT-AS1 in GC tumorigenesis, revealing the vital pathway of NNT-AS1/miR-424/E2F1 axis.

In summary, our study validated that the overexpression of NNT-AS1 is observed in GC tissue and cells. The ectopic high-expressed NNT-AS1 indicated the poor prognosis of GC patients. On the molecular level, NNT-AS1 promotes the oncogenesis and cycle progress of GC cells via miR-424/E2F1 axis.

ACKNOWLEDGEMENT

This work was supported by Project of National Natural Science Foundation of China (No. 81472714), Project of international scientific and technological cooperation research of Henan Province (No. 182102410023).

CONFLICTS OF INTEREST

All the authors declare that they have no competing interests.

ORCID

Xiao-Bing Chen http://orcid.org/0000-0002-4295-7316

REFERENCES

1. Ji C, Zhao Y, Kou YW, et al. Cathepsin F knockdown induces proliferation and inhibits apoptosis in gastric cancer cells. Oncol Res. 2018;26:83-93.
2. Ji S, Zhang Y, Yang B. YEATS domain containing 4 promotes gastric cancer cell proliferation and mediates tumor progression via activating the Wnt/beta-catenin signaling pathway. Oncol Res. 2017;25:1633-1641.
3. Allum W, Lordick F, Alsina M, et al. ECCO essential requirements for quality cancer care: oesophageal and gastric cancer. Crit Rev Oncol Hematol. 2018;122:179-193.

4. Li D, Lo W, Rudloff U. Merging perspectives: genotype-directed molecular therapy for hereditary diffuse gastric cancer (HDGC) and E-cadherin-EGFR cross-talk. Clin Transl Med. 2018;7:7.

5. Pan Y, Chen K, Yu WH, et al. Laparoscopic gastrectomy for elderly patients with gastric cancer: a systematic review with meta-analysis. Medicine. 2018;97:e0007.

6. Sitarz R, Skierucha M, Mielko J, Offerhaus GJA, Maciejewski R, Polkowski WP. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res. 2018;10:239-248.

7. Gao YL, Zhao ZS, Zhang MY, Han LJ, Dong YJ, Xu B. Long non-coding RNA 01296 aggravates gastric cancer cells progress through Wnt/beta-catenin signaling pathway in vivo. Mol Cell Biochem. 2018;646:227-233.

8. Wu X, Zhang P, Zhu H, Li S, Chen X, Shi L. Long noncoding RNA UCA1 targets miR-122 to promote proliferation migration, and EMT through epigenetically silencing p27 and sponging miR-335-5p. Mol Gene Genom. 2018;327:45-56.

9. Li C, Dong J, Han Z, Zhang K. MicroRNA-219-5p represses the proliferation, migration, and invasion of gastric cancer cells by targeting the LRH-1/Wnt/beta-catenin signaling pathway. OncoLett. 2017;25:617-627.

10. Qin N, Tong GF. Sun LW, Xu XL. Long noncoding RNA, contributes to proliferation and migration in gastric cancer. Mol Med Rep. 2018;646:227-233.

11. Qin QH, Yin ZQ, Li Y, Wang BG, Zhang MF. Long intergenic non-coding RNA 01296 aggravates gastric cancer cells progress through miR-122/MMP-9. Biomed Pharmacother. 2018;97:450-457.

12. Ye H, Lin J, Li Y, Lin X, Lu H. Overexpression of long non-coding RNA NNT-AS1 correlates with tumor progression and poor prognosis in osteosarcoma. Cell Physiol Biochem. 2018;45:1904-1914.

13. Yang R, Li P, Zhang G, Lu C, Wang H, Zhao G. Long non-coding RNA XLOC_008466 functions as an oncogene in human non-small cell lung cancer by targeting miR-874. Cell Physiol Biochem. 2017;42:126-136.

14. Meng YB, He X, Huang YF, Wu QN, Zhou YC, Hao DJ. Long non-coding RNA CRNDE promotes multiple myeloma cell growth by suppressing miR-451. OncoLett. 2017;25:1207-1214.

15. Qin N, Tong GF, Sun LW, Xu XL. Long noncoding RNA MEG3 suppresses glioma cell proliferation, migration, and invasion by acting as a competing endogenous RNA of miR-19a. OncoLett. 2017;25:1471-1478.

16. Tan HY, Wang C, Liu G, Zhou X. Long noncoding RNA NEAT1-modulated miR-506 regulates gastric cancer development through targeting STAT3. J Cell Biochem. 2018;25:526-533.

17. Hua F, Liu S, Zhu L, Ma N, Jiang S, Yang J. Highly expressed long non-coding RNA NNT-AS1 promotes cell proliferation and invasion through Wnt/beta-catenin signaling pathway in cervical cancer. Biomed Pharmacother. 2017;92:1128-1134.

18. Lu YB, Jiang Q, Yang MY, Zhou JX, Zhang Q. Long noncoding RNA NNT-AS1 promotes hepatocellular carcinoma progression and metastasis through miR-363/CDK6 axis. Oncotarget. 2017:8:88804-88814.

19. Wang Q, Yang L, Hu X, et al. Upregulated NNT-AS1, a long noncoding RNA, contributes to proliferation and migration of colorectal cancer cells in vitro and in vivo. Oncotarget. 2017;8:3443-3453.

20. Shan Y, Ying R, Jia Z, et al. LINC00522 promotes gastric cancer cell proliferation and metastasis via activating the Wnt/beta-catenin signaling pathway. Oncol Res. 2017;25:1589-1599.

21. Shi J, Zhang Y, Jin N, Li Y, Wu S, Xu L. MicroRNA-221-3p plays an oncogenic role in gastric carcinoma by inhibiting PTEN expression. Oncol Res. 2017;25:523-536.

22. Wang G, Fu Y, Liu G, Ye Y, Zhang X. miR-218 inhibits proliferation, migration, and EMT of gastric cancer cells by targeting WASF3. Oncol Res. 2017;25:355-364.

23. Duan F, Jiang J, Song C, et al. Functional long non-coding RNAs associated with gastric cancer susceptibility and evaluation of the epidemiological efficacy in a central Chinese population. Gene. 2018;646:227-233.

24. Sun Y, Jin JG, Mi WY, Zhang SR, Meng Q, Zhang ST. Long noncoding RNA UCA1 targets miR-122 to promote proliferation migration, and invasion of glioma cells. OncoL Res. 2018;26:103-110.

25. Zhang LL, Zhang LF, Guo XH, Zhang DZ, Yang F, Fan YY. Downregulation of miR-335-5p by Long Noncoding RNA ZEB1-AS1 in gastric cancer promotes tumor proliferation and invasion. DNA Cell Biol. 2018;37:46-52.

26. Xu TP, Wang YF, Xiong WL, et al. E2F1 induces TINCR transcriptional activity and accelerates gastric cancer progression via activation of TINCR/STAU1/CDKN2B signaling axis. Cell Death Dis. 2017;8:e2837.

27. Wei S, Li Q, Wang L, Zhang L, Xu Z. miR-424-5p promotes proliferation of gastric cancer by targeting Smad3 through TGF-beta signaling pathway. Oncotarget. 2016;7:75185-75196.

28. Chen Y, Wei G, Xia H, Tang Q, Bi F. Long noncoding RNAATB promotes cell proliferation, migration and invasion in gastric cancer. Mol Med Rep. 2018;17:1940-1946.

29. Yan K, Tian J, Shi W, Xia H, Zhu Y. LncRNA SNHG6 is associated with poor prognosis of gastric cancer and promotes cell proliferation and EMT through epigenetically silencing p27 and sponging miR-101-3p. Cell Physiol Biochem. 2017;42:999-1012.

How to cite this article: Chen B, Zhao Q, Guan L, et al. Long non-coding RNA NNT-AS1 sponges miR-424/E2F1 to promote the tumorigenesis and cell cycle progression of gastric cancer. J Cell Mol Med. 2018;22:4751-4759. https://doi.org/10.1111/jcmm.13726